These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 8713795)
1. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795 [TBL] [Abstract][Full Text] [Related]
2. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors. Gandossi E; Lunven C; Gauffeny C; Roome NO; Berry CN Thromb Haemost; 1998 Nov; 80(5):840-4. PubMed ID: 9843181 [TBL] [Abstract][Full Text] [Related]
3. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Berry CN; Girardot C; Lecoffre C; Lunven C Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788 [TBL] [Abstract][Full Text] [Related]
4. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. Kawai H; Yamamoto T; Hara H; Tamao Y Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187 [TBL] [Abstract][Full Text] [Related]
6. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571 [TBL] [Abstract][Full Text] [Related]
7. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro. Gandossi E; Lunven C; Berry CN Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104 [TBL] [Abstract][Full Text] [Related]
8. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor. Cella G; Girolami A; Sasahara AA Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510 [No Abstract] [Full Text] [Related]
9. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501 [TBL] [Abstract][Full Text] [Related]
10. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction. Imiya M; Matsuo T Thromb Res; 1997 Oct; 88(2):245-50. PubMed ID: 9361377 [TBL] [Abstract][Full Text] [Related]